Weight & metabolism
Tirzepatide
Zepbound, Mounjaro
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA for chronic weight management (Zepbound) and type 2 diabetes (Mounjaro). It is backed by large, multi-year clinical trial programs.
Key facts
- Commonly discussed for: weight management and type 2 diabetes.
- Evidence (A): SURMOUNT-1 randomized 2,539 adults and found 15% to 20.9% average weight loss at 72 weeks across doses versus 3.1% with placebo, within a larger phase 3 program.
- FDA status: FDA-approved. FDA approved Zepbound for chronic weight management on November 8, 2023, and FDA reports the tirzepatide shortage is resolved.
- Legitimate access: Rx brand.
- Last reviewed: October 1, 2026.